Anatomic Pathology of Hepatocellular Carcinoma: Impact on Prognosis and Response to Therapy

Clinics in Liver Disease

Volumn 15, Issue 2, 2011, Pages 245-259

  Roskams, Tania ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Dysplastic nodules; Early HCC; Glutamine synthetase; Glypican3; Hepatic progenitor cells; HSP70; K19; Liver biopsy

Indexed keywords

4 DIMETHYLAMINOAZOBENZENE; ABC TRANSPORTER; AFLATOXIN; ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; BETA CATENIN; BEVACIZUMAB; BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; CD34 ANTIGEN; CISPLATIN; CYTOKERATIN 14; CYTOKERATIN 18; CYTOKERATIN 19; CYTOKERATIN 7; CYTOKERATIN 8; CYTOKERATIN AE1; CYTOKERATIN AE3; EPITHELIAL CELL ADHESION MOLECULE; ERLOTINIB; GLUTAMATE AMMONIA LIGASE; GLYPICAN 3; HEAT SHOCK PROTEIN 70; NOTCH RECEPTOR; PROTEIN P53; SORAFENIB; THY 1 ANTIGEN; UNINDEXED DRUG; VIMENTIN; WNT PROTEIN;

APOPTOSIS; ARTERY BLOOD FLOW; ASPERGILLUS; BASEMENT MEMBRANE; BILE DUCT CARCINOMA; BILE DUCT STONE; BILIARY TRACT DISEASE; CANCER INVASION; CANCER RISK; CANCER STEM CELL; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CHRONIC INFLAMMATION; CHRONIC LIVER DISEASE; CLONORCHIS SINENSIS; COLONY FORMING CELL; CYTOPLASM; ECHOGRAPHY; ENZYME HISTOCHEMISTRY; EXPERIMENTAL ANIMAL; FALSE POSITIVE RESULT; FASCIOLIASIS; GASTROINTESTINAL TRACT; GENE EXPRESSION; HEPATITIS B; HEPATITIS C; HISTOGENESIS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INTOXICATION; LIVER BIOPSY; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DEVELOPMENT; LIVER HISTOLOGY; LIVER INJURY; LIVER REGENERATION; LIVER SINUSOID; LIVER TRANSPLANTATION; LIVER TUMOR; METABOLIC DISORDER; METASTASIS; MICRODISSECTION; MICROSCOPY; NEOPLASM; NONALCOHOLIC FATTY LIVER; NONHUMAN; OPISTHORCHIS VIVERRINI; OXIDATIVE STRESS; PHENOTYPE; PRACTICE GUIDELINE; PRIMARY SCLEROSING CHOLANGITIS; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR RECURRENCE; UNSPECIFIED SIDE EFFECT; VASCULARIZATION; VIRUS HEPATITIS;

ANIMALS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; NEOPLASTIC STEM CELLS;

EID: 79959294956     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2011.03.004     Document Type: Review

References (65)

1. Bruix J., Llovet J.M. Two decades of advances in hepatocellular carcinoma research. Semin Liver Dis 2010, 30:1-2.
2. Hayashi P.H., Trotter J.F., Forman L., et al. Impact of pretransplant diagnosis of hepatocellular carcinoma on cadaveric liver allocation in the era of MELD. Liver Transpl 2004, 10:42-48.
3. Wiesner R.H., Freeman R.B., Mulligan D.C. Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. Gastroenterology 2004, 127:S261-S267.
4. Compagnon P., Grandadam S., Lorho R., et al. Liver transplantation for hepatocellular carcinoma without preoperative tumor biopsy. Transplantation 2008, 86:1068-1076.
5. International consensus on the pathologic diagnosis of early hepatocellular carcinoma: a report of the International Concensus Group for Hepatocellular Neoplasia. Hepatology 2009, 49:658-664. International Concensus Group for Hepatocellular Neoplasia.
6. Kojiro M., Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis 2005, 25:133-142.
7. Roskams T., Kojiro M. Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. Semin Liver Dis 2010, 30:17-25.
8. Terminology of nodular hepatocellular lesions. International Working Party. Hepatology 1995, 22:983-993.
9. Yoon D.S., Jeong J., Park Y.N., et al. Expression of biliary antigen and its clinical significance in hepatocellular carcinoma. Yonsei Med J 1999, 40:472-477.
10. Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 2006, 25:3818-3822.
11. Alison M.R., Lovell M.J. Liver cancer: the role of stem cells. Cell Prolif 2005, 38:407-421.
12. Theise N.D., Yao J.L., Harada K., et al. Hepatic 'stem cell' malignancies in adults: four cases. Histopathology 2003, 43:263-271.
13. Theise N.D., Saxena R., Portmann B.C., et al. The canals of Hering and hepatic stem cells in humans. Hepatology 1999, 30:1425-1433.
14. Kuwahara R., Kofman A.V., Landis C.S., et al. The hepatic stem cell niche: identification by label-retaining cell assay. Hepatology 2008, 47(6):1994-2002.
15. Roskams T.A., Theise N.D., Balabaud C., et al. Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology 2004, 39:1739-1745.
16. Roskams T. Different types of liver progenitor cells and their niches. J Hepatol 2006, 45:1-4.
17. Ros J.E., Libbrecht L., Geuken M., et al. High expression of MDR1, MRP1, and MRP3 in the hepatic progenitor cell compartment and hepatocytes in severe human liver disease. J Pathol 2003, 200:553-560.
18. Vander Borght S., Libbrecht L., Katoonizadeh A., et al. Breast cancer resistance protein (BCRP/ABCG2) is expressed by progenitor cells/reactive ductules and hepatocytes and its expression pattern is influenced by disease etiology and species type: possible functional consequences. J Histochem Cytochem 2006, 54:1051-1059.
19. Falkowski O., An H.J., Ianus I.A., et al. Regeneration of hepatocyte 'buds' in cirrhosis from intrabiliary stem cells. J Hepatol 2003, 39:357-364.
20. Libbrecht L., Desmet V., Van Damme B., et al. Deep intralobular extension of human hepatic 'progenitor cells' correlates with parenchymal inflammation in chronic viral hepatitis: can 'progenitor cells' migrate?. J Pathol 2000, 192:373-378.
21. Roskams T. Progenitor cell involvement in cirrhotic human liver diseases: from controversy to consensus. J Hepatol 2003, 39:431-434.
22. Wiemann S.U., Satyanarayana A., Tsahuridu M., et al. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J 2002, 16:935-942.
23. Lowes K.N., Brennan B.A., Yeoh G.C., et al. Oval cell numbers in human chronic liver diseases are directly related to disease severity. Am J Pathol 1999, 154:537-541.
24. Lowes K.N., Croager E.J., Olynyk J.K., et al. Oval cell-mediated liver regeneration: role of cytokines and growth factors. J Gastroenterol Hepatol 2003, 18:4-12.
25. Roskams T.A., Libbrecht L., Desmet V.J. Progenitor cells in diseased human liver. Semin Liver Dis 2003, 23:385-396.
26. Roskams T., Yang S.Q., Koteish A., et al. Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol 2003, 163:1301-1311.
27. Hixson D.C., Brown J., McBride A.C., et al. Differentiation status of rat ductal cells and ethionine-induced hepatic carcinomas defined with surface-reactive monoclonal antibodies. Exp Mol Pathol 2000, 68:152-169.
28. Desmet V. Experimentele levercarcinogenese: Histochemische studie 1963, Presses Academiques Europeennes, Brussels.
29. Dumble M.L., Croager E.J., Yeoh G.C., et al. Generation and characterization of p53 null transformed hepatic progenitor cells: oval cells give rise to hepatocellular carcinoma. Carcinogenesis 2002, 23:435-445.
30. Libbrecht L., Desmet V., Van Damme B., et al. The immunohistochemical phenotype of dysplastic foci in human liver: correlation with putative progenitor cells. J Hepatol 2000, 33:76-84.
31. Hamburger A.W., Salmon S.E. Primary bioassay of human tumor stem cells. Science 1977, 197:461-463.
32. Spee B., Carpino G., Schotanus B.A., et al. Characterisation of the activated liver progenitor cell niche, potential involvement of Wnt and Notch signalling. Gut 2010, 59(2):247-257.
33. Wicha M.S., Liu S., Dontu G. Cancer stem cells: an old idea-a paradigm shift. Cancer Res 2006, 66:1883-1890. [discussion: 1895-6].
34. Taniguchi H., Chiba T. Stem cells and cancer in the liver. Dis Markers 2008, 24:223-229.
35. Armengol C., Cairo S., Fabre M., et al. Wnt signaling and hepatocarcinogenesis: the hepatoblastoma model. Int J Biochem Cell Biol 2011, 43(2):265-270.
36. Yang W., Yan H.X., Chen L., et al. Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res 2008, 68:4287-4295.
37. Libbrecht L., Desmet V., Roskams T. Preneoplastic lesions in human hepatocarcinogenesis. Liver Int 2005, 25:16-27.
38. Hsia C.C., Evarts R.P., Nakatsukasa H., et al. Occurrence of oval-type cells in hepatitis B virus-associated human hepatocarcinogenesis. Hepatology 1992, 16:1327-1333.
39. Uenishi T., Kubo S., Yamamoto T., et al. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci 2003, 94:851-857.
40. Van Eyken P., Sciot R., Paterson A., et al. Cytokeratin expression in hepatocellular carcinoma: an immunohistochemical study. Hum Pathol 1988, 12:562-568.
41. Wu P.C., Lai V.C., Fang J.W., et al. Hepatocellular carcinoma expressing both hepatocellular and biliary markers also expresses cytokeratin 14, a marker of bipotential progenitor cells. J Hepatol 1999, 31:965-966.
42. Durnez A., Verslype C., Nevens F., et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 2006, 49:138-151.
43. Zhuang P.Y., Zhang J.B., Zhu X.D., et al. Two pathologic types of hepatocellular carcinoma with lymph node metastasis with distinct prognosis on the basis of CK19 expression in tumor. Cancer 2008, 112(12):2740-2748.
44. Yamashita T., Forgues M., Wang W., et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008, 68:1451-1461.
45. Aishima S., Kuroda Y., Nishihara Y., et al. Proposal of progression model for intrahepatic cholangiocarcinoma: clinicopathologic differences between hilar type and peripheral type. Am J Surg Pathol 2007, 31:1059-1067.
46. Ding S.J., Li Y., Tan Y.X., et al. From proteomic analysis to clinical significance: overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis. Mol Cell Proteomics 2004, 3:73-81.
47. Aishima S., Nishihara Y., Kuroda Y., et al. Histologic characteristics and prognostic significance in small hepatocellular carcinoma with biliary differentiation: subdivision and comparison with ordinary hepatocellular carcinoma. Am J Surg Pathol 2007, 31:783-791.
48. Lee J.S., Chu I.S., Heo J., et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004, 40:667-676.
49. Lee J.S., Heo J., Libbrecht L., et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006, 12(4):410-416.
50. Ma S., Chan K.W., Hu L., et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007, 132:2542-2556.
51. Ma S., Lee T.K., Zheng B.J., et al. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008, 27:1749-1758.
52. Dan Y.Y., Riehle K.J., Lazaro C., et al. Isolation of multipotent progenitor cells from human fetal liver capable of differentiating into liver and mesenchymal lineages. Proc Natl Acad Sci U S A 2006, 103:9912-9917.
53. Yang Z.F., Ho D.W., Ng M.N., et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008, 13:153-166.
54. Yang Z.F., Ngai P., Ho D.W., et al. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology 2008, 47:919-928.
55. Yamashita T., Ji J., Budhu A., et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009, 136:1012-1024.
56. Yamashita T., Budhu A., Forgues M., et al. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res 2007, 67:10831-10839.
57. Roskams T., Ros J.E., Libbrecht L., et al. High Expression of MDR1, MRP1, and MRP3 in the hepatic progenitor cell compartment and hepatocytes in severe human liver disease. Hepatology 2001, 34:479.
58. Chiba T., Kita K., Zheng Y.W., et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 2006, 44:240-251.
59. Shi G.M., Xu Y., Fan J., et al. Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. J Cancer Res Clin Oncol 2008, 134:1155-1163.
60. Vander Borght S., Komuta M., Libbrecht L., et al. Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver Int 2008, 28:1370-1380.
61. Wakamatsu T., Nakahashi Y., Hachimine D., et al. The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins. Int J Oncol 2007, 31:1465-1472.
62. Hu C., Li H., Li J., et al. Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. Carcinogenesis 2008, 29:2289-2297.
63. Folmer Y., Schneider M., Blum H.E., et al. Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-ABCC2 antisense constructs. Cancer Gene Ther 2007, 14:875-884.
64. Siegel A. Moving targets in hepatocellular carcinoma: hepatic progenitor cells as novel targets for tyrosine kinase inhibitors. Gastroenterology 2008, 135:733-735.
65. Schirmacher P, Bedossa P, Roskams T, et al. Fighting the bushfire in HCC trials. J Hepatology 2011, in press.